Pricing Log in Create free account
Saturday 17 October 2026 Export SGMOQ’s income statement to Excel — free account

Sangamo Therapeutics, Inc.

SGMOQ Healthcare Biotechnology

Sangamo Therapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $39.6 million, down 31.6% from fiscal 2024. In the quarter to March 2026, revenue fell 77.6%, EPS grew 42.9% and free cash flow grew 26.2%, each against the same quarter a year earlier.

0.11 0.03 −21.43%
Market cap
$41.9M
P/E
0.0×
Fwd P/E
−1.0×
Dividend yield
—
F-score
3/9
Altman Z
−43.35
Beneish M
−5.11
Dividend safety
n/a
Overview Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Insider Decisions trades per month

Total sells 0.11
Totals in millions of $.
Dec 25 Mar 26 Jun 26 Sep 26
Buy — — — — — — — — — — — —
Sell — — — — — 2 — — — — — —
Insider Ownership 0.00%

Capital & Financial Ratios $m

Market Cap 41.89
Revenue 34.56
Net Income (123.33)
Free Cash Flow (90.46)
Net Debt (27.59)
Current Ratio 0.70 (below 1: weak)
Debt/Equity 0.00 (at or below 0.5: strong)
P/E ratio 0.00
Fwd P/E (0.96) (negative: loss-making)
P/S ratio 1.24
P/B ratio 0.00
Past 5Y EPS Growth —
This Y EPS Growth 56.82% (at or above 15%: strong)
Next Y EPS Growth 71.05% (at or above 15%: strong)
Next Y revenue growth (74.97%) (below 0%: weak)
Next 5Y EPS Growth 73.79% (at or above 15%: strong)

Green and red mark values outside typical ranges. How we judge →

Valuation vs history

EV/Sales, ten years
EV/Sales is 1.2×, against a ten-year median of 5.6×; over the ten years it ranged from −0.1× in 2023 to 45.2× in 2018.
P/S against its own 10 years 10.50%
10-year low 10-year high
EV/Sales against its own 10 years 9.13%
10-year low 10-year high

Dividends

Payout Ratio —
Annual Dividend Rate —
Annual Dividend Yield —
total individual payouts
2025 Powerpack
2024 Powerpack
2023 Powerpack
2022 Powerpack
2021 Powerpack
2020 Powerpack
2019 Powerpack
2017 Powerpack
predictions special payouts not included in total or ratios

Assets vs Liabilities $m

2023 2024 2025 Q'26
Cash 81 42 21 28
Receivables 1 1 0 1
Inventory — — — —
Other 3 4 10 5
94 52 36 37
2023 2024 2025 Q'26
Payables 15 15 14 19
ST’ Debt — — — —
Other — — — —
48 46 42 53

Compound Annual Growth %

10y 5y 3y
Sales 0.00% (19.66%) (29.17%)
Cash Flow 0.00% 0.00% 0.00%
Earnings 0.00% 0.00% 0.00%
Book Value 0.00% 0.00% 0.00%

Revenue $m

Mar Jun Sep Dec Year
’26 1 — — — —
’25 6 18 1 14 40
’24 0 0 49 8 58
’23 158 7 9 2 176
’22 28 29 26 27 111
’21 26 28 29 28 111
’20 13 22 58 26 118
Fiscal quarters ending in the months shown.

Operating Cash Flow $m

Mar Jun Sep Dec Year
’26 (19) — — — —
’25 (26) (18) (28) (24) (97)
’24 (49) (27) 12 (3) (67)
’23 (66) (61) (47) (51) (225)
’22 (59) (54) (54) (57) (224)
’21 (69) (53) (59) (53) (233)
’20 (19) 160 33 (4) 170
Fiscal quarters ending in the months shown.

Free Cash Flow $m

Mar Jun Sep Dec Year
’26 (19) — — — —
’25 (26) (18) (29) (24) (97)
’24 (49) (27) 12 (4) (67)
’23 (76) (66) (50) (53) (246)
’22 (62) (59) (58) (65) (244)
’21 (76) (60) (65) (56) (257)
’20 (23) 157 29 (8) 155
Fiscal quarters ending in the months shown.

EPS $

Mar Jun Sep Dec Year
’26 (0.08) — — — —
’25 (0.14) (0.08) (0.11) (0.11) (0.44)
’24 (0.27) (0.18) 0.04 (0.11) (0.49)
’23 0.12 (0.66) (0.59) (0.34) (1.48)
’22 (0.30) (0.29) (0.34) (0.32) (1.25)
’21 (0.32) (0.33) (0.33) (0.26) (1.23)
’20 (0.37) (0.26) (0.01) (0.29) (0.90)
Fiscal quarters ending in the months shown.

Target Price Range

Analyst price targets

Recommendation Rating

2
1Buy 2 3Hold 4 5Sell

Ten years at a glance Fiscal years to December

Group Line 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 Trend 2026e 2027e 2028e
Price, $
Price, $ Low 2.65 3.00 9.00 6.26 4.81 7.05 2.72 0.29 0.30 0.38

Analyst estimates 2026–2028

Powerpack
High 9.22 18.40 27.50 13.91 19.43 17.53 7.99 3.76 3.18 1.51
People
People Employees 131 182 302 354 413 431 478 405 183 142
Revenue/emp, $m 0.15 0.20 0.28 0.29 0.29 0.26 0.23 0.44 0.32 0.28
Income, $m
Income, $m Revenue 19 37 84 102 118 111 111 176 58 40
Gross margin, % 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00
EBT (72) (55) (69) (95) (121) (178) (192) (263) (98) (123)
EBT margin, % (369.65) (149.23) (81.57) (93.16) (102.19) (160.79) (172.37) (149.18) (169.74) (312.25)
Net income (72) (55) (69) (95) (121) (178) (192) (258) (98) (123)
Depreciation 1 1 (3) 5 13 20 19 109 9 8
Per share, $
Per share, $ Revenue 0.27 0.47 0.87 0.91 0.88 0.77 0.72 1.01 0.29 0.14
Earnings (1.02) (0.70) (0.70) (0.85) (0.90) (1.23) (1.25) (1.48) (0.49) (0.44)
Cash flow (0.93) 0.14 0.38 (1.29) 1.26 (1.61) (1.45) (1.29) (0.33) (0.35)
Capex (0.01) (0.05) (0.44) (0.18) (0.11) (0.16) (0.13) (0.12) 0.00 0.00
Free cash flow (0.94) 0.10 (0.07) (1.47) 1.15 (1.77) (1.58) (1.41) (0.33) (0.35)
Book value 1.93 2.41 3.79 3.86 3.70 2.60 1.91 0.48 0.11 (0.05)
Shares, m 71 78 97 112 134 145 154 174 202 280
Valuation, ×
Valuation, × P/E 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
P/S 11.28 37.48 13.18 9.16 17.76 9.79 4.35 0.55 3.56 2.98
P/B 1.61 7.29 3.03 2.17 4.22 2.89 1.64 1.18 9.04 0.00
EV/Sales 4.13 31.50 8.77 5.89 12.56 6.64 2.11 0.25 3.31 3.15
EV/FCF (1.20) 155.06 (113.65) (3.66) 9.57 (2.87) (0.96) (0.18) (2.63) (1.27)
Cash, $m
Cash, $m Operating cash flow (66) 11 37 (144) 170 (233) (224) (225) (67) (97)
Capex (1) (4) (43) (21) (15) (23) (20) (21) 0 0
Free cash flow (67) 7 (7) (165) 155 (257) (244) (246) (67) (97)
Balance, $m
Balance, $m Working capital 136 204 332 336 516 271 189 47 6 (7)
Total debt 4 25 28 41 38 44 39 — — —
Net debt (139) (219) (372) (362) (641) (377) (278) (81) (42) (21)
Shareholders’ equity 136 188 367 433 497 375 295 83 23 (14)
Returns, %
Returns, % ROA (38.20) (24.55) (15.58) (15.50) (15.35) (21.47) (29.94) (70.85) (73.38) (152.35)
ROIC 0.00 0.00 0.00 (93.56) 0.00 0.00 (726.08) (9,085.05) 0.00 0.00
ROE (43.61) (33.67) (24.62) (23.80) (26.02) (40.86) (57.37) (136.47) (185.39) (2,891.84)
Negative figures in brackets.

All 10 years →

Fiscal years to Dec 2025 · latest quarter Mar 2026

Charts ten years each

Sangamo Therapeutics, Inc. vs peers in Biotechnology (Q) = latest quarter vs a year earlier

Company Market cap P/E Fwd P/E Revenue growth (Q) EPS growth (Q) FCF growth (Q) Gross margin (Q) EBIT margin (Q) Compare
SER Serina Therapeutics, Inc. $45.5M — (loss-making) — (loss-making) +2,500.00% (above 0%: growing) n/m −76.82% (below 0%: shrinking) 100.00% 0.00% Compare
ANVS Annovis Bio, Inc. $44.8M — (loss-making) — — n/m −329.18% (below 0%: shrinking) — 0.00% Compare
ALDX Aldeyra Therapeutics, Inc. $44.5M — (loss-making) — — n/m +46.09% (above 0%: growing) 0.00% 0.00% Compare
CELU Celularity, Inc. $43.2M — (loss-making) — (loss-making) −66.34% (below 0%: shrinking) n/m +148.35% (above 0%: growing) 62.25% (263.47%) Compare
DWTX Dogwood Therapeutics, Inc $42.5M — (loss-making) — — n/m +10.31% (above 0%: growing) — 0.00% Compare
SGMOQ Sangamo Therapeutics, Inc. $41.9M — (loss-making) — (loss-making) −77.60% (below 0%: shrinking) n/m +26.21% (above 0%: growing) 100.00% (2,215.40%)
VERU Veru Inc. $41.6M — (loss-making) — (loss-making) +287.06% (above 0%: growing) n/m +0.27% (above 0%: growing) 34.92% 0.00% Compare
TIL Instil Bio, Inc. $41.6M — (loss-making) — — n/m +68.62% (above 0%: growing) 0.00% 0.00% Compare
GRCE Grace Therapeutics, Inc. $41.0M — (loss-making) — (loss-making) +5,127.27% (above 0%: growing) n/m −78.85% (below 0%: shrinking) 0.00% 0.00% Compare
Median of peers $42.8M — — +1,393.53% — +5.29% 17.46% 0.00%

All 614 Biotechnology stocks →

Sangamo Therapeutics, Inc. (SGMOQ) key facts

  • Concern: Sangamo Therapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $39.6 million, down 31.6% from fiscal 2024.
  • Concern: Sangamo Therapeutics, Inc. reported a net loss of $122.9 million, or a loss of $0.44 per share, for fiscal 2025.
  • Sangamo Therapeutics, Inc. (SGMOQ) is a Biotechnology company in the Healthcare sector.
  • As of October 16, 2026, SGMOQ traded at $0.11, a market capitalization of $41.9 million.
  • Trailing earnings are negative, so a P/E ratio is not meaningful; the stock trades at 1.2× sales.
  • Return on equity was −2,891.8% and debt-to-equity 0.00.
  • Its Piotroski F-score is 3 out of 9 and its Altman Z-score is −43.35 (distress zone) for fiscal 2025.

Source: company filings (standardised) and stockrow calculations.

Sangamo Therapeutics, Inc. (SGMOQ) Latest News

24 Jun

Impact 5 ·
stockrow.com/SGMOQ · Data as of Mar 31, 2026 · For information only; not investment advice. · © 2026 stockrow.com